Introduction
Reproductive and hormone-related risk factors for epithelial ovarian cancer (EOC) have been extensively investigated (reviewed in ref 1) . However, EOC is increasingly recognized as a heterogeneous disease and risk factor differences across EOC subtypes, such as the recently proposed dualistic pathway of ovarian carcinogenesis (i.e., type I, type II 1, 2 ) and main histologic subgroups (i.e., serous, mucinous, endometrioid), are not well understood.
The dualistic model of ovarian carcinogenesis suggests that EOC develops by two pathways: 2 type I tumors are less aggressive and are thought to develop from defined precursor lesions (i.e. borderline tumors, endometriosis), while type II tumors are more aggressive, rapidly metastasize, and have no well-defined precursor lesion within the ovary. 3 Type I EOC includes low grade serous and endometrioid EOC, as well as mucinous, clear cell, and malignant Brenner tumors, whereas type II tumors are primarily high grade serous or endometrioid EOC. To our knowledge, only one prior study has investigated reproductive and hormonerelated risk factors by the dualistic pathway; this study observed significant heterogeneity in risk factors between type I and type II tumors. 4 For example, parity exerted a stronger protective effect against type I tumors, whereas associations between duration of oral contraceptive (OC) use and breastfeeding duration were stronger for type II tumors. 4 These findings have not yet been replicated.
Prior studies suggest risk factors for epithelial ovarian cancer may differ by histologic subtype. 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] For example, a collaborative reanalysis of 45 epidemiologic studies found the risk reduction afforded by OC use was evident for serous, endometrioid and clear cell, but not mucinous, tumors 13 and an analysis in the Ovarian Cancer Cohort Consortium (OCAC) found a positive association between body mass index (BMI) and risk of invasive endometrioid, mucinous and clear cell, but not high grade serous, tumors. 12 However, heterogeneous associations between BMI and EOC histologic subgroups have not been observed in all studies. 14 The extent to which reproductive and hormone-related factors impact risk differentially by histologic subtype remains unclear.
An improved understanding of heterogeneity in risk across EOC subtypes will ultimately improve our understanding of the etiology of this lethal disease. Therefore, we present a detailed investigation of reproductive and hormone-related risk factors and EOC by the dualistic pathway of carcinogenesis and major histologic subtypes in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
Methods
The EPIC cohort was established between 1992-2000 at 23 centers in 10 countries: Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom. Details of the study design have been published previously. 15, 16 Briefly, more than 500,000 men and women between the ages of approximately 25-75 years of age were enrolled; participants provided detailed information on diet and lifestyle, including data on reproductive and menstrual history, hormone use, and medical history. In all countries except France, Germany, and Greece, as well as the center of Naples, Italy, follow-up is based on record linkage; the end of follow-up was the date of last follow-up for cancer incidence and vital status (2004) (2005) (2006) (2007) (2008) (2009) 
Study Population and Case Ascertainment
Participants were excluded if they reported history of prior cancer at recruitment (except nonmelanoma skin cancer), had incomplete baseline data, or reported bilateral oophorectomy at baseline, leaving a study population of 334,225 women. We additionally excluded women missing data on all investigated reproductive and hormone-related risk factors (n=99). Our final study population included 334,126 women.
Cases were defined as women diagnosed after recruitment with an incident epithelial borderline tumor (C569) or invasive ovarian (C569), fallopian tube (C570) or peritoneal cancer (C480, C481, C482, C488) according to 
Exposure Assessment
Data on age at menarche, age at menopause, parity and number of full-term pregnancies, breast feeding, menstrual cycle regularity, OC use and duration, menopausal hormone replacement therapy (MHT) use, and hysterectomy were collected at baseline using standardized questionnaires. Height (cm) and weight (kg) were measured according to standardized procedures, except for the Oxford cohort, the Norwegian cohort, and part of the French cohort, where height and weight were predominantly self-reported. 17 For participants from the Oxford cohort, where only self-reported data were available, linear regression models were used to recalibrate values using age-specific measurements from subjects with both measured and selfreported body measures. These measures were used to calculate body mass index (BMI; kg/m 2 ).
Statistical Analysis
We used Cox proportional hazards models to estimate the association between reproductive and We investigated the major individual components associated with duration of ovulatory lifespan and EOC risk. 19 These analyses included ages at menarche and menopause, duration of OC use, and duration of full-term pregnancies (number of full-term pregnancies *0.75), mutually adjusted and as a composite variable to estimate total duration of ovulatory lifespan. We further examined associations between number of full-term pregnancies, age at first and last pregnancy, and time since last pregnancy in mutually adjusted models investigating risk associations among parous women. We used the approach described by Heuch et al. 20 to ensure that observed risk estimates were not biased by multi-collinearity. In these analyses, nulliparous women were assigned to the reference category of age at first and last pregnancy, and time since last pregnancy, and indicator variables for parity were included in the model such that effect estimates reflect risk among parous women. Sensitivity analyses were conducted excluding women diagnosed with fallopian tube or peritoneal cancers.
P-values <0.05 were considered statistically significant; all p-values were two-sided. All analyses were conducted in SAS 9.3 (Cary, NC).
Results
Baseline characteristics by tumor invasiveness and the dualistic model are presented in Table 1 .
Briefly, women who remained free of EOC were somewhat younger at recruitment than those diagnosed with invasive disease during follow-up (median age at recruitment, non-cases: 51 years; invasive cases: 55 years), and a higher proportion of women subsequently diagnosed with invasive EOC were postmenopausal at recruitment (63%), relative to women diagnosed with borderline tumors (33%) and to women who remained free of EOC (45%). As expected, the majority of both borderline (58%) and invasive (55%) tumors were of serous histology. A total of 81% of type II tumors were serous, whereas type I tumors were predominantly of mucinous (43%) and clear cell (31%) histology.
Ever full-term pregnancy was differentially associated with risk across subgroups defined by type I and type II status (type I vs. II: ever full-term pregnancy, p het =0.02) ( Table 2 ). We observed a significant inverse association between ever full-term pregnancy and type I tumors (ever vs. never full-term pregnancy:
Relative We additionally examined exposures related to total ovulatory lifespan (ages at menarche and menopause, OC use, and pregnancy) in mutually adjusted models ( repeated these analyses restricted to women postmenopausal at recruitment, given that the data on reproductive history on these women was more complete (i.e., age at menopause was known, no additional pregnancies).
Results were somewhat attenuated after restricting the analysis to women postmenopausal at recruitment (i. We observed no heterogeneity by histologic subgroup in analyses examining factors related to ovulatory lifespan (all p het ≥0.10; Table 5 ). However, older age at menarche was associated with reduced risk of We analysed the associations between the following pregnancy-related variables and risk among parous women in mutually adjusted models: number of full-term pregnancies, age at first and last pregnancy, and time since last pregnancy. We observed significant heterogeneity in the associations between age at first full-term pregnancy and type I and II tumors (p=0.02; Supplemental between the examined pregnancy-related variables by the examined histologic subtypes (Supplemental Table   2 ). None of the pregnancy-related variables were significantly associated with the EOC subgroups, with the exception of a significant positive association between time since last pregnancy and serous tumors (>30 vs. 
Discussion
We observed limited heterogeneity in risk between reproductive and hormone-related factors and epithelial ovarian cancer subtypes in this large, prospective investigation. Full-term pregnancy was significantly inversely associated with type I tumors, but not with borderline tumors or type II EOC.
Associations for full-term pregnancy were not significantly different across main histologic subgroups (serous, mucinous, endometrioid and clear cell tumors). In analyses considering invasive EOC as the outcome, the associations with established reproductive factors were confirmed (i.e., parity, OC use).
The prevailing assumption that ovarian cancer originates in the ovary has been supplanted, with emerging data suggesting that many "ovarian" cancers originate in the fallopian tube. We hypothesized heterogeneity in risk associations given these differences between ovarian cancer subtypes.
One prior investigation has evaluated reproductive risk factors for EOC by the type I/II pathways, 4 and one additional study investigated "rapidly fatal" (within 3 years; proxy for type II) vs. "less aggressive" (proxy for type I) disease. 21 Consistent with these prior analyses, we observed a somewhat stronger protective effect for ever full-term pregnancy for type I vs. type II disease and a suggestively stronger positive association between older age at menopause and type I vs. type II tumors. We did not replicate prior findings of heterogeneity suggesting stronger inverse associations for breastfeeding 4 or duration of OC use 4,21 with type II disease. However, case numbers were limited in some subgroups. Larger studies or pooled analyses investigating risk factors by tumor aggressiveness are needed to better characterize EOC risk.
Parity and number of full-term pregnancies are hypothesized to impact risk of EOC via (1) reduction in the number of ovulatory cycles (i.e., reducing incessant ovulation), 22 (2) the well-established changes in the hormonal milieu during gestation, and (3) the cell clearance hypothesis. 23 It is plausible that pregnancy differentially impacts risk of type I vs. type II tumors, given the proposed different pathways leading to the development of these tumors. We observed a stronger association between ever full-term pregnancy and type I vs. type II EOC. Given that type I tumors are slower growing malignancies, it is plausible that exposure to the "cell clearance" and hormonal milieu of a single pregnancy is sufficient to afford protection against these tumors. Given the rapid development of type II tumors (predominantly high-grade serous), more recent pregnancy-associated "cell clearance", represented by shorter time since last pregnancy, may be the most relevant pregnancy-related exposure for risk reduction in this subgroup. This is in line with the significant positive association between time since last pregnancy and serous tumors observed in this study. However, we did not observe significant heterogeneity across subgroups for time since last pregnancy, nor did we observe a significant association between time since last pregnancy and type II tumors.
Age at menopause was suggestively more strongly associated with type I tumors in our study. Type I tumors are more slowly growing malignancies than type II disease and it is plausible that type I tumors are more sensitive to the premenopausal hormonal milieu (i.e., relatively high endogenous estrogens). To our knowledge, there are no data to date examining the association between circulating estrogens and ovarian cancer by the dualistic pathway. However, in our previous investigation on the role of androgens and EOC by subtype, we observed a significant positive association between androstenedione and type I EOC, and an inverse association for type II disease. 24 Androstenedione is a precursor to estradiol, and higher androstenedione may represent a higher estrogen environment. 1 Stratified by age at recruitment and study center and adjusted for ever full-term pregnancy, ever OC use, menopausal status at recruitment, age at menopause, and ever HRT use ²P for trend on continuous scale 3 P for subtype heterogeneity comparing type I and type II tumors. 4 Among parous women 5 Among postmenopausal women 3 Age at menopause was entered in the model with a minus sign to compare with other factors. 4 For women not postmenopausal at recruitment, age at menopause was replaced by age at recruitment. 5 Calculated as: (number of FTP) x 0.75. 6 Calculated as: (age at menopause -age at menarche -duration of OC use -cumulative duration of FTP), and entered into the model with a minus sign; Age and center stratified and further adjusted for menopausal status at recruitment and ever HRT use. 7 Calculated as: (age at menopause -age at menarche -duration of OC use -cumulative duration of FTP), and entered into the model with a minus sign; Age and center stratified and adjusted for ever HRT use. 1 Stratified by age at recruitment and study center and adjusted for ever full-term pregnancy, ever OC use, menopausal status at recruitment, age at menopause, and ever HRT use ²P for trend on continuous scale 3 P for subtype heterogeneity comparing serous, mucinous, endometrioid, and clear cell tumors. 4 Among parous women 5 Among postmenopausal women 
